Research Article

Prevalence and Trajectory of COVID-19-Associated Hypercoagulability Using Serial Thromboelastography in a South African Population

Table 2

Non-TEG characteristics.

VariablesAll patients, n = 41HC, n = 22Non-HC, n = 19 value

Age (year)61 [50–67]62.5 [51–68]56 [46–64]0.22
Female, n (%)26 (63)14/42 (34%)12/41 (29%)

Blood parameters
 Haemoglobin (g/dL)13.2 [11.6–14.2]12.05 [10.6–14.00]13.3 [13.00–15.00]0.06
 LDH (U/L)752 [489–901]759 [495–842]651 [489–989]0.98
 D-dimers (mg/L)0.585 [0.38–1.39]0.58 [0.38–1.0]0.96 [0.39–2.12]0.45
 Fibrinogen (mg/dL)6.7 [5.6–7.8]6.7 [6–7.9]6.5 [4.9–7.3]0.40
 Platelets (x 109/L)249 [195–292]265 [237–342]221 [167–280]0.02
 PT (sec)13.45 [13.0–14.4]13.9 [13.0–14.4]13.4 [12.9–14.5]0.75
 aPTT (sec)25.6 [22.35–30.7]24.7 [21.9–28.7]25.85 [23.2–32.0]0.60
 INR1.11 [1.06–1.19]1.13 [1.06–1.18]1.11 [1.06–1.2]0.90

Enoxaparin, n = 39n = 39n = 21n = 180.62
 Therapeutic, n (%)20 (51)10 (48)10 (56)
 Prophylactic n (%)19 (49)11 (52)8 (44)

Severity
 Severe19 (46)10 (53)9 (47)
 Critically ill22 (54)12 (55)10 (45)0.9
 SOFA3 [2–4]3 [2–4]2 [2–5]0.49
 SAPS222 [18–30]26 [21–31]21 [18–27]0.13
 DIC2 [0–2]2 [0–2]2 [0–3]0.16
 SIC2 [2–3]2 [2–3]2 [2–3]0.87

Mortality, n (%)18 (43.9)8 (44.4)10 (55.6)0.30
Resolution of hypoxemia by day 10, n (%)13 (32)8 (36)5 (26)0.49

Statistically significant. Data are expressed as median (interquartile range) or count (percentage). HC hypercoagulable, DM diabetes mellitus, LDH lactate dehydrogenase, PT prothrombin time, aPTT activated partial thromboplastin time, INR international normalised ratio, SOFA sequential organ failure assessment, SAPS2 simplified acute physiology score 2, DIC disseminated intravascular coagulopathy, SIC sepsis-induced coagulopathy.